CD8A and cancer: These findings confirm our preliminary results in a smaller series of BRAF-mCRCs [17], suggesting that a pronounced host immune reaction is not unique to MSI BRAF-mCRC and that simultaneous evaluation of MSI status and CD8 T-cell content could be a useful strategy for identifying a prognostically distinct subgroup of patients with potential eligibility for cancer immunotherapy drugs.